The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Ro 201724     4-[(3-butoxy-4-methoxy...

Synonyms: CHEMBL18701, AG-J-66621, AG-L-66735, SureCN1022716, BSPBio_001358, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Ro 20 1724

  • Expression of these cDNAs in Escherichia coli and monkey COS-7 cells demonstrated that the encoded cAMP-PDEs had similar affinities for the cAMP substrate and were equally sensitive to a number of PDE inhibitors (rolipram greater than Ro 20-1724 greater than cilostamide) [1].
  • Treatment of atopic dermatitis MNL with varying concentrations of the cAMP PDE inhibitor Ro 20-1724 resulted in progressively decreasing amounts of IgE synthesis, statistically significant at the 10(-4) M and 10(-5) M concentrations [2].
  • Ro 20-1724 and other cyclic nucleotide-altering agents may have therapeutic potential in the future treatment of psoriasis [3].
  • Inhibition of type IV phosphodiesterase by Ro 20-1724 attenuates endotoxin-induced acute renal failure [4].
  • Rolipram, Ro 20-1724, and ICI 63-197 (group 1) caused hypothermia, hypoactivity, forepaw shaking, grooming, and head twitches [5].
 

Psychiatry related information on Ro 20 1724

 

High impact information on Ro 20 1724

  • CGRP, in the presence of the phosphodiesterase inhibitor Ro 20-1724, increased phosphorylation of the alpha and delta subunits of the AChR [7].
  • Preliminary incubation of fibroblasts with 8-bromo cGMP or phosphodiesterase inhibitors, including 3-isobutyl-1-methylxanthine, Ro 20-1724, and cilostamide, however, prevented the ANF suppression of cAMP [8].
  • The PGE(2)-induced vasodilation was potentiated by the phosphodiesterase inhibitor Ro 20-1724 and was mimicked by 11-deoxy-PGE(1) (0.01 to 1 nmol/L) [9].
  • Incubation of cultured VSMCs with a PDE4-selective inhibitor, Ro 20-1724, markedly potentiated both the antimigratory effect and the increase in cAMP caused by forskolin [10].
  • When 100 microM Ro-20-1724 was applied to the HERG 4M channel, missing all PKA sites, there was no significant shift in the activation curve, and the current amplitude was not reduced [11].
 

Chemical compound and disease context of Ro 20 1724

  • Pretreatment with milrinone or Ro-20-1724 enhanced LPS-induced increases in plasma tumor necrosis factor-alpha and lactate, inhibited the LPS-induced tachycardia, and exacerbated the acute LPS-induced fall in GFR [12].
  • Repeated administration of dexamethasone and Ro 20-1724 with each OvA exposure attenuated all of the chronic inflammatory responses: early and late phase responses, hyperreactivity and eosinophilia [13].
 

Biological context of Ro 20 1724

  • The widely used phosphodiesterase inhibitor MIX (1-methyl 3-isobutyl xanthine) blocked insulin antagonism of cAMP-stimulated glycogenolysis in rat hepatocytes but other phosphodiesterase inhibitors including Ro 20-1724 had no effect [14].
  • A calmodulin-stimulated phosphodiesterase activity was inhibited by MIX, 7-BzMIX, 8-MeOMeMIX, and MB 22948 (IC50 values = 1-10 microM) but was not inhibited by IIX and Ro 20-1724 [15].
  • Insulin did suppress lipolysis stimulated by Ro 20-1724, an inhibitor of soluble cAMP phosphodiesterase activity [16].
  • Selective inhibition of cAMP hydrolysis by Ro 20-1724 and its greater effectiveness in elevating cAMP levels in slices of psoriatic epidermis is one explanation for its clinical superiority in treating psoriatic lesions [17].
  • In animals pretreated with endotoxin, Ro 20-1724 attenuated norepinephrine-induced increases in mesenteric vascular resistance (P = .054) and decreases in mesenteric blood flow (P < .01) [18].
 

Anatomical context of Ro 20 1724

  • However, addition of 70 microM Ro 20-1724 to the adherence assay did not potentiate the inhibitory effects of CGS 21680 and NECA on PMA-stimulated neutrophil adherence [19].
  • The granulocyte response to the phosphodiesterase inhibitor RO 20-1724 in asthma [20].
  • This monocyte fraction accounted for most of the elevated leukocyte-PDE activity and was a cytosolic, cAMP-specific, low Michaelis constant, calcium-calmodulin-dependent enzyme, inhibited by the cAMP-PDE inhibitor, Ro 20-1724 [21].
  • The various effects of the phosphodiesterase inhibitor D-4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone (RO-20-1724) on fat cell metabolism were examined and compared to those obtained with 1-methyl-3-isobutylxanthine (IBMX) [22].
  • We next examined the effect of the phosphodiesterase inhibitor Ro 20-1724 on interleukin-4 production and found a significant reduction in cultures of atopic mononuclear leukocytes [23].
 

Associations of Ro 20 1724 with other chemical compounds

 

Gene context of Ro 20 1724

 

Analytical, diagnostic and therapeutic context of Ro 20 1724

References

  1. Properties and hormonal regulation of two structurally related cAMP phosphodiesterases from the rat Sertoli cell. Swinnen, J.V., Tsikalas, K.E., Conti, M. J. Biol. Chem. (1991) [Pubmed]
  2. Phosphodiesterase inhibition by Ro 20-1724 reduces hyper-IgE synthesis by atopic dermatitis cells in vitro. Cooper, K.D., Kang, K., Chan, S.C., Hanifin, J.M. J. Invest. Dermatol. (1985) [Pubmed]
  3. Ro 20-1724: an agent that significantly improves psoriatic lesions in double-blind clinical trials. Stawiski, M.A., Rusin, L.J., Burns, T.L., Weinstein, G.D., Voorhees, J.J. J. Invest. Dermatol. (1979) [Pubmed]
  4. Inhibition of type IV phosphodiesterase by Ro 20-1724 attenuates endotoxin-induced acute renal failure. Begany, D.P., Carcillo, J.A., Herzer, W.A., Mi, Z., Jackson, E.K. J. Pharmacol. Exp. Ther. (1996) [Pubmed]
  5. Characteristic behavioural alterations in rats induced by rolipram and other selective adenosine cyclic 3', 5'-monophosphate phosphodiesterase inhibitors. Wachtel, H. Psychopharmacology (Berl.) (1982) [Pubmed]
  6. Phosphodiesterase inhibitors potentiate opiate-antagonist discrimination by morphine-dependent rats. Holtzman, S.G. Pharmacol. Biochem. Behav. (1989) [Pubmed]
  7. Calcitonin gene-related peptide regulates phosphorylation of the nicotinic acetylcholine receptor in rat myotubes. Miles, K., Greengard, P., Huganir, R.L. Neuron (1989) [Pubmed]
  8. Atrial natriuretic factor reduces cyclic adenosine monophosphate content of human fibroblasts by enhancing phosphodiesterase activity. Lee, M.A., West, R.E., Moss, J. J. Clin. Invest. (1988) [Pubmed]
  9. Biphasic actions of prostaglandin E(2) on the renal afferent arteriole : role of EP(3) and EP(4) receptors. Tang, L., Loutzenhiser, K., Loutzenhiser, R. Circ. Res. (2000) [Pubmed]
  10. Synergistic inhibition of vascular smooth muscle cell migration by phosphodiesterase 3 and phosphodiesterase 4 inhibitors. Palmer, D., Tsoi, K., Maurice, D.H. Circ. Res. (1998) [Pubmed]
  11. Deletion of protein kinase A phosphorylation sites in the HERG potassium channel inhibits activation shift by protein kinase A. Thomas, D., Zhang, W., Karle, C.A., Kathöfer, S., Schöls, W., Kübler, W., Kiehn, J. J. Biol. Chem. (1999) [Pubmed]
  12. Lipopolysaccharide-induced acute renal failure in conscious rats: effects of specific phosphodiesterase type 3 and 4 inhibition. Jonassen, T.E., Graebe, M., Promeneur, D., Nielsen, S., Christensen, S., Olsen, N.V. J. Pharmacol. Exp. Ther. (2002) [Pubmed]
  13. PDE4 inhibition and a corticosteroid in chronically antigen exposed conscious guinea-pigs. Danahay, H., Broadley, K.J. Clin. Exp. Allergy (1998) [Pubmed]
  14. Methylisobutylxanthine blocks insulin antagonism of cAMP-stimulated glycogenolysis at a site distinct from phosphodiesterase. Evidence favoring an insulin-insensitive calcium release mechanism. Gabbay, R.A., Lardy, H.A. J. Biol. Chem. (1986) [Pubmed]
  15. Identification of the phosphodiesterase regulated by muscarinic cholinergic receptors of 1321N1 human astrocytoma cells. Tanner, L.I., Harden, T.K., Wells, J.N., Martin, M.W. Mol. Pharmacol. (1986) [Pubmed]
  16. Antilipolytic action of insulin: role of cAMP phosphodiesterase activation. Elks, M.L., Manganiello, V.C. Endocrinology (1985) [Pubmed]
  17. Papaverine and Ro 20-1724 inhibit cyclic nucleotide phosphodiesterase activity and increase cyclic AMP levels in psoriatic epidermis in vitro. Rusin, L.J., Duell, E.A., Voorhees, J.J. J. Invest. Dermatol. (1978) [Pubmed]
  18. Treatment with the type IV phosphodiesterase inhibitor Ro 20-1724 protects renal and mesenteric blood flow in endotoxemic rats treated with norepinephrine. Carcillo, J.A., Herzer, W.A., Mi, Z., Thomas, N.J., Jackson, E.K. J. Pharmacol. Exp. Ther. (1996) [Pubmed]
  19. Phorbol ester-stimulated adherence of neutrophils to endothelial cells is reduced by adenosine A2 receptor agonists. Felsch, A., Stöcker, K., Borchard, U. J. Immunol. (1995) [Pubmed]
  20. The granulocyte response to the phosphodiesterase inhibitor RO 20-1724 in asthma. Busse, W.W., Anderson, C.L. J. Allergy Clin. Immunol. (1981) [Pubmed]
  21. Immunochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitis. Chan, S.C., Reifsnyder, D., Beavo, J.A., Hanifin, J.M. J. Allergy Clin. Immunol. (1993) [Pubmed]
  22. Differential effects of two phosphodiesterase inhibitors on fat cell metabolism. Shechter, Y. Endocrinology (1984) [Pubmed]
  23. Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition. Chan, S.C., Li, S.H., Hanifin, J.M. J. Invest. Dermatol. (1993) [Pubmed]
  24. Inhibition of chemotactic peptide-induced neutrophil adhesion to vascular endothelium by cAMP modulators. Derian, C.K., Santulli, R.J., Rao, P.E., Solomon, H.F., Barrett, J.A. J. Immunol. (1995) [Pubmed]
  25. Administration of a cAMP phosphodiesterase 4 inhibitor enhances antidepressant-induction of BDNF mRNA in rat hippocampus. Fujimaki, K., Morinobu, S., Duman, R.S. Neuropsychopharmacology (2000) [Pubmed]
  26. Occupancy of adenosine receptors raises cyclic AMP alone and in synergy with occupancy of chemoattractant receptors and inhibits membrane depolarization. Cronstein, B.N., Kramer, S.B., Rosenstein, E.D., Korchak, H.M., Weissmann, G., Hirschhorn, R. Biochem. J. (1988) [Pubmed]
  27. Effect of carbachol and 56 mm-potassium chloride on the cyclic AMP-mediated induction of tyrosine hydroxylase in neuroblastoma cells in culture. Tank, A.W., Weiner, N. J. Neurochem. (1981) [Pubmed]
  28. Role of phosphodiesterase isoenzymes in the control of renin secretion: effects of selective enzyme inhibitors. Reid, I.A. Curr. Pharm. Des. (1999) [Pubmed]
  29. Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity. Rose, R.J., Liu, H., Palmer, D., Maurice, D.H. Br. J. Pharmacol. (1997) [Pubmed]
  30. Structural basis for specificity and potency of xanthine derivatives as activators of the CFTR chloride channel. Chappe, V., Mettey, Y., Vierfond, J.M., Hanrahan, J.W., Gola, M., Verrier, B., Becq, F. Br. J. Pharmacol. (1998) [Pubmed]
  31. Tumour necrosis factor alpha-induced oxidative burst in neutrophils adherent to fibronectin: effects of cyclic AMP-elevating agents. Ottonello, L., Morone, M.P., Dapino, P., Dallegri, F. Br. J. Haematol. (1995) [Pubmed]
  32. The effect of selective phosphodiesterase inhibitors, alone and in combination, on a murine model of allergic asthma. Clayton, R.A., Dick, C.A., Mackenzie, A., Nagasawa, M., Galbraith, D., Hastings, S.F., MacKenzie, S.J. Respir. Res. (2004) [Pubmed]
  33. A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. Weishaar, R.E., Cain, M.H., Bristol, J.A. J. Med. Chem. (1985) [Pubmed]
 
WikiGenes - Universities